Bidirectional Association between Nonalcoholic Fatty Liver Disease and Gallstone Disease: A Cohort Study

Yoosoo Chang, Yoo-Hun Noh, Byung-Seong Suh, Yejin Kim, Eunju Sung, Hyun-Suk Jung, Chan-Won Kim, Min-Jung Kwon, Kyung Eun Yun, Jin-Won Noh, Hocheol Shin, Yong Kyun Cho, Seungho Ryu, Yoosoo Chang, Yoo-Hun Noh, Byung-Seong Suh, Yejin Kim, Eunju Sung, Hyun-Suk Jung, Chan-Won Kim, Min-Jung Kwon, Kyung Eun Yun, Jin-Won Noh, Hocheol Shin, Yong Kyun Cho, Seungho Ryu

Abstract

Nonalcoholic fatty liver disease (NAFLD) and gallstone disease (GD) are often found to coexist but the sequential relationship of NAFLD and GD to each other remains controversial. We prospectively evaluated the bidirectional relationship of NAFLD with GD. A cohort study was performed on Korean adults who underwent a health checkup and were followed annually or biennially for a mean of 6.0 years. Fatty liver and gallstones were diagnosed by ultrasound. NAFLD was defined as hepatic steatosis on ultrasonography in the absence of excessive alcohol use or other identifiable causes. The NAFLD severity was determined by non-invasive fibrosis markers. Among 283,446 participants without either gallstones or cholecystectomy at baseline, 6440 participants developed gallstones. Among 219,641 participants without NAFLD at baseline, 49,301 participants developed NAFLD. The multivariable-adjusted hazard ratio (95% confidence interval) for incident gallstone comparing the NAFLD group vs. the non-NAFLD group was 1.26 (1.17⁻1.35). Increased non-invasive fibrosis markers of NAFLD were positively associated with an increased incidence of gallstones in a graded and dose-responsive manner (p-trend < 0.01). The multivariable-adjusted hazard ratios (95% confidence intervals) for incident NAFLD comparing gallstone and cholecystectomy to no GD were 1.14 (1.07⁻1.22) and 1.17 (1.03⁻1.33), respectively. This large-scale cohort study of young and middle-aged individuals demonstrated a bidirectional association between NAFLD and GD. NAFLD and its severity were independently associated with an increased incidence of gallstones, while GD and cholecystectomy were also associated with incident NAFLD. Our findings indicate that the conditions may affect each other, requiring further studies to elucidate the potential mechanisms underlying this association.

Keywords: bidirectional relationship; cohort study; gallstones; insulin resistance; nonalcoholic fatty liver disease.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flow diagram for the selection of study subjects.

References

    1. Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., Charlton M., Sanyal A.J. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American gastroenterological association, American association for the study of liver diseases, and American college of gastroenterology. Gastroenterology. 2012;142:1592–1609. doi: 10.1053/j.gastro.2012.04.001.
    1. Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: Summary of an AASLD single topic conference. Hepatology. 2003;37:1202–1219. doi: 10.1053/jhep.2003.50193.
    1. Nascimbeni F., Ballestri S., Machado M.V., Mantovani A., Cortez-Pinto H., Targher G., Lonardo A. Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Expert. Rev. Gastroenterol. Hepatol. 2018;12:351–367. doi: 10.1080/17474124.2018.1415756.
    1. Younossi Z., Henry L. Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality. Gastroenterology. 2016;150:1778–1785. doi: 10.1053/j.gastro.2016.03.005.
    1. Anstee Q.M., Targher G., Day C.P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 2013;10:330–344. doi: 10.1038/nrgastro.2013.41.
    1. Ballestri S., Nascimbeni F., Romagnoli D., Lonardo A. The independent predictors of non-alcoholic steatohepatitis and its individual histological features: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol. Res. 2016;46:1074–1087.
    1. Ballestri S., Zona S., Targher G., Romagnoli D., Baldelli E., Nascimbeni F., Roverato A., Guaraldi G., Lonardo A. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J. Gastroenterol. Hepatol. 2016;31:936–944. doi: 10.1111/jgh.13264.
    1. Italian Association for the Study of the Liver AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Dig. Liver Dis. 2017;49:471–483. doi: 10.1016/j.dld.2017.01.147.
    1. Lonardo A., Nascimbeni F., Mantovani A., Targher G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J. Hepatol. 2018;68:335–352. doi: 10.1016/j.jhep.2017.09.021.
    1. Vanni E., Bugianesi E., Kotronen A., De Minicis S., Yki-Jarvinen H., Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig. Liver Dis. 2010;42:320–330. doi: 10.1016/j.dld.2010.01.016.
    1. Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet. Diabetes Endocrinol. 2014;2:901–910. doi: 10.1016/S2213-8587(14)70032-4.
    1. Di Ciaula A., Wang D.Q., Portincasa P. An update on the pathogenesis of cholesterol gallstone disease. Curr. Opin. Gastroenterol. 2018;34:71–80. doi: 10.1097/MOG.0000000000000423.
    1. Loria P., Lonardo A., Lombardini S., Carulli L., Verrone A., Ganazzi D., Rudilosso A., D’Amico R., Bertolotti M., Carulli N. Gallstone disease in non-alcoholic fatty liver: Prevalence and associated factors. J. Gastroenterol. Hepatol. 2005;20:1176–1184. doi: 10.1111/j.1440-1746.2005.03924.x.
    1. Ramos-De la Medina A., Remes-Troche J.M., Roesch-Dietlen F.B., Perez-Morales A.G., Martinez S., Cid-Juarez S. Routine liver biopsy to screen for nonalcoholic fatty liver disease (NAFLD) during cholecystectomy for gallstone disease: Is it justified? J. Gastrointest. Surg. 2008;12:2097–2102. doi: 10.1007/s11605-008-0704-7.
    1. Shen S.S., Gong J.J., Wang X.W., Chen L., Qin S., Huang L.F., Chen Y.Q., Ren H., Yang Q.B., Hu H.D. Promotional effect of nonalcoholic fatty liver disease on Gallstone disease: A systematic review and meta-analysis. Turk. J. Gastroenterol. 2017;28:31–39. doi: 10.5152/tjg.2016.0357.
    1. Jaruvongvanich V., Sanguankeo A., Upala S. Significant association between gallstone disease and nonalcoholic fatty liver disease: A systematic review and meta-analysis. Dig. Dis. Sci. 2016;61:2389–2396. doi: 10.1007/s10620-016-4125-2.
    1. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., Natale S., Vanni E., Villanova N., Melchionda N., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–923. doi: 10.1053/jhep.2003.50161.
    1. Nervi F., Arrese M. Cholecystectomy and NAFLD: Does gallbladder removal have metabolic consequences? Am. J. Gastroenterol. 2013;108:959–961. doi: 10.1038/ajg.2013.84.
    1. Biddinger S.B., Haas J.T., Yu B.B., Bezy O., Jing E., Zhang W., Unterman T.G., Carey M.C., Kahn C.R. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat. Med. 2008;14:778–782. doi: 10.1038/nm1785.
    1. Ahmed M.H., Ali A. Nonalcoholic fatty liver disease and cholesterol gallstones: Which comes first? Scand. J. Gastroenterol. 2014;49:521–527. doi: 10.3109/00365521.2014.894119.
    1. Ryan M.C., Wilson A.M., Slavin J., Best J.D., Jenkins A.J., Desmond P.V. Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetes Care. 2005;28:1222–1224. doi: 10.2337/diacare.28.5.1222.
    1. Chen J.Y., Hsu C.T., Liu J.H., Tung T.H. Clinical predictors of incident gallstone disease in a Chinese population in Taipei, Taiwan. BMC Gastroenterol. 2014;14:83. doi: 10.1186/1471-230X-14-83.
    1. Liu J., Lin H., Zhang C., Wang L., Wu S., Zhang D., Tang F., Xue F., Liu Y. Non-alcoholic fatty liver disease associated with gallstones in females rather than males: A longitudinal cohort study in Chinese urban population. BMC Gastroenterol. 2014;14:213. doi: 10.1186/s12876-014-0213-y.
    1. Housset C., Chretien Y., Debray D., Chignard N. Functions of the gallbladder. Compr. Physiol. 2016;6:1549–1577.
    1. Chang Y., Jung H.S., Cho J., Zhang Y., Yun K.E., Lazo M., Pastor-Barriuso R., Ahn J., Kim C.W., Rampal S., et al. Metabolically Healthy obesity and the development of nonalcoholic fatty liver disease. Am. J. Gastroenterol. 2016;111:1133–1140. doi: 10.1038/ajg.2016.178.
    1. Chang Y., Cho Y.K., Kim Y., Sung E., Ahn J., Jung H.S., Yun K.E., Shin H., Ryu S. Non-heavy drinking and worsening of non-invasive fibrosis markers in nonalcoholic fatty liver disease: A cohort study. Hepatology. 2018 doi: 10.1002/hep.30170.
    1. World Health Organization, Regional Office for the Western Pacific . The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. Health Communications Australia Pty Limited; Sydney, Australia: 2000.
    1. Angulo P., Hui J.M., Marchesini G., Bugianesi E., George J., Farrell G.C., Enders F., Saksena S., Burt A.D., Bida J.P., et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846–854. doi: 10.1002/hep.21496.
    1. McPherson S., Stewart S.F., Henderson E., Bugianesi E., George J., Farrell G.C., Enders F., Saksena S., Burt A.D., Bida J.P., et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59:1265–1269. doi: 10.1136/gut.2010.216077.
    1. Shah A.G., Lydecker A., Murray K., Tetri B.N., Contos M.J., Sanyal A.J. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2009;7:1104–1112. doi: 10.1016/j.cgh.2009.05.033.
    1. Wai C.T., Greenson J.K., Fontana R.J., Kalbfleisch J.D., Marrero J.A., Conjeevaram H.S., Lok A.S. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–526. doi: 10.1053/jhep.2003.50346.
    1. Mathiesen U.L., Franzen L.E., Aselius H., Resjo M., Jacobsson L., Foberg U., Fryden A., Bodemar G. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig. Liver Dis. 2002;34:516–522. doi: 10.1016/S1590-8658(02)80111-6.
    1. Everhart J.E., Khare M., Hill M., Maurer K.R. Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology. 1999;117:632–639. doi: 10.1016/S0016-5085(99)70456-7.
    1. Royston P., Parmar M.K. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat. Med. 2002;21:2175–2197. doi: 10.1002/sim.1203.
    1. Ahmed M., Diggory R. Acalculous gallbladder disease: The outcomes of treatment by laparoscopic cholecystectomy. Ann. R. Coll. Surg. Engl. 2011;93:209–212. doi: 10.1308/003588411X563402.
    1. Schwesinger W.H., Diehl A.K. Changing indications for laparoscopic cholecystectomy. Stones without symptoms and symptoms without stones. Surg. Clin. North Am. 1996;76:493–504. doi: 10.1016/S0039-6109(05)70456-4.
    1. Bedogni G., Bellentani S., Miglioli L., Masutti F., Passalacqua M., Castiglione A., Tiribelli C. The fatty liver index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33. doi: 10.1186/1471-230X-6-33.
    1. Arrese M., Cortes V., Barrera F., Nervi F. Nonalcoholic fatty liver disease, cholesterol gallstones, and cholecystectomy: New insights on a complex relationship. Curr. Opin. Gastroenterol. 2018;34:90–96. doi: 10.1097/MOG.0000000000000416.
    1. Lee Y.C., Wu J.S., Yang Y.C., Chang C.S., Lu F.H., Chang C.J. Moderate to severe, but not mild, nonalcoholic fatty liver disease associated with increased risk of gallstone disease. Scand. J. Gastroenterol. 2014;49:1001–1006. doi: 10.3109/00365521.2014.920912.
    1. Qiao Q.H., Zhu W.H., Yu Y.X., Huang F.F., Chen L.Y. Nonalcoholic fatty liver was associated with asymptomatic gallstones in a Chinese population. Medicine (Baltimore) 2017;96:e7853. doi: 10.1097/MD.0000000000007853.
    1. Fracanzani A.L., Valenti L., Russello M., Miele L., Bertelli C., Bellia A., Masetti C., Cefalo C., Grieco A., Marchesini G., et al. Gallstone disease is associated with more severe liver damage in patients with non-alcoholic fatty liver disease. PLoS ONE. 2012;7:e41183. doi: 10.1371/journal.pone.0041183.
    1. Qin J.-J., Ding W.-J. Nonalcoholic fatty liver disease and its relevant factors increased the risk of gallstone disease: A systematic review and meta-analysis. Int. J. Clin. Exp. Med. 2016;9:3009–3016.
    1. Cortes V., Quezada N., Uribe S., Arrese M., Nervi F. Effect of cholecystectomy on hepatic fat accumulation and insulin resistance in non-obese Hispanic patients: A pilot study. Lipids Health Dis. 2017;16:129. doi: 10.1186/s12944-017-0525-3.
    1. Seppala-Lindroos A., Vehkavaara S., Hakkinen A.M., Goto T., Westerbacka J., Sovijarvi A., Halavaara J., Yki-Jarvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J. Clin. Endocrinol. Metab. 2002;87:3023–3028. doi: 10.1210/jcem.87.7.8638.
    1. Feldman A., Eder S.K., Felder T.K., Kedenko L., Paulweber B., Stadlmayr A., Huber-Schonauer U., Niederseer D., Stickel F., Auer S., et al. Clinical and metabolic characterization of lean Caucasian subjects with non-alcoholic fatty liver. Am. J. Gastroenterol. 2017;112:102–110. doi: 10.1038/ajg.2016.318.
    1. Chen L.Y., Qiao Q.H., Zhang S.C., Chen Y.H., Chao G.Q., Fang L.Z. Metabolic syndrome and gallstone disease. World J. Gastroenterol. 2012;18:4215–4220. doi: 10.3748/wjg.v18.i31.4215.
    1. Simonen P., Kotronen A., Hallikainen M., Sevastianova K., Makkonen J., Hakkarainen A., Lundbom N., Miettinen T.A., Gylling H., Yki-Jarvinen H. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J. Hepatol. 2011;54:153–159. doi: 10.1016/j.jhep.2010.05.037.
    1. Min H.K., Kapoor A., Fuchs M., Mirshahi F., Zhou H., Maher J., Kellum J., Warnick R., Contos M.J., Sanyal A.J. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 2012;15:665–674. doi: 10.1016/j.cmet.2012.04.004.
    1. Halldestam I., Kullman E., Borch K. Incidence of and potential risk factors for gallstone disease in a general population sample. Br. J. Surg. 2009;96:1315–1322. doi: 10.1002/bjs.6687.
    1. Shaffer E.A. Epidemiology and risk factors for gallstone disease: Has the paradigm changed in the 21st century? Curr. Gastroenterol. Rep. 2005;7:132–140. doi: 10.1007/s11894-005-0051-8.
    1. Shaffer E.A. Gallstone disease: Epidemiology of gallbladder stone disease. Best Pract. Res. Clin. Gastroenterol. 2006;20:981–996. doi: 10.1016/j.bpg.2006.05.004.
    1. Kim M.H., Lim B.C., Myung S.J., Lee S.K., Ohrr H.C., Kim Y.T., Roe I.H., Kim J.H., Chung J.B., Kim C.D., et al. Epidemiological study on Korean gallstone disease: A nationwide cooperative study. Dig. Dis. Sci. 1999;44:1674–1683. doi: 10.1023/A:1026643817349.
    1. Musso G., Gambino R., Cassader M. Recent insights into hepatic lipid metabolism in non–alcoholic fatty liver disease (NAFLD) Prog. Lipid Res. 2009;48:1–26. doi: 10.1016/j.plipres.2008.08.001.
    1. Almond H.R., Vlahcevic Z.R., Bell C.C.Jr., Gregory D.H., Swell L. Bile acid pools, kinetics and biliary lipid composition before and after cholecystectomy. N. Engl. J. Med. 1973;289:1213–1216. doi: 10.1056/NEJM197312062892302.
    1. Trauner M., Claudel T., Fickert P., Moustafa T., Wagner M. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig. Dis. 2010;28:220–224. doi: 10.1159/000282091.
    1. Wagner M., Zollner G., Trauner M. Nuclear receptors in liver disease. Hepatology. 2011;53:1023–1034. doi: 10.1002/hep.24148.
    1. Barrera F., Azocar L., Molina H., Schalper K.A., Ocares M., Liberona J., Villarroel L., Pimentel F., Perez-Ayuso R.M., Nervi F., et al. Effect of cholecystectomy on bile acid synthesis and circulating levels of fibroblast growth factor 19. Ann. Hepatol. 2015;14:710–721.
    1. Ruhl C.E., Everhart J.E. Relationship of non-alcoholic fatty liver disease with cholecystectomy in the US population. Am. J. Gastroenterol. 2013;108:952–958. doi: 10.1038/ajg.2013.70.
    1. Zweers S.J., Booij K.A., Komuta M., Roskams T., Gouma D.J., Jansen P.L., Schaap F.G. The human gallbladder secretes fibroblast growth factor 19 into bile: Towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology. 2012;55:575–583. doi: 10.1002/hep.24702.
    1. Bhatnagar S., Damron H.A., Hillgartner F.B. Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J. Biol. Chem. 2009;284:10023–10033. doi: 10.1074/jbc.M808818200.
    1. Fu L., John L.M., Adams S.H., Yu X.X., Tomlinson E., Renz M., Williams P.M., Soriano R., Corpuz R., Moffat B., et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology. 2004;145:2594–2603. doi: 10.1210/en.2003-1671.
    1. Kullak-Ublick G.A., Paumgartner G., Berr F. Long-term effects of cholecystectomy on bile acid metabolism. Hepatology. 1995;21:41–45. doi: 10.1002/hep.1840210109.
    1. Alisi A., Ceccarelli S., Panera N., Prono F., Petrini S., De Stefanis C., Pezzullo M., Tozzi A., Villani A., Bedogni G., et al. Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease. PLoS ONE. 2013;8:e67160. doi: 10.1371/journal.pone.0067160.
    1. Ballestri S., Nascimbeni F., Baldelli E., Marrazzo A., Romagnoli D., Lonardo A. NAFLD as a sexual dimorphic disease: Role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv. Ther. 2017;34:1291–1326. doi: 10.1007/s12325-017-0556-1.
    1. Lammert F., Gurusamy K., Ko C.W., Miquel J.F., Mendez-Sanchez N., Portincasa P., van Erpecum K.J., van Laarhoven C.J., Wang D.Q. Gallstones. Nat. Rev. Dis. Primers. 2016;2:16024. doi: 10.1038/nrdp.2016.24.
    1. Huang J., Chang C.H., Wang J.L., Kuo H.K., Lin J.W., Shau W.Y., Lee P.H. Nationwide epidemiological study of severe gallstone disease in Taiwan. BMC Gastroenterol. 2009;9:63. doi: 10.1186/1471-230X-9-63.
    1. Key T.J., Appleby P.N., Reeves G.K., Roddam A., Dorgan J.F., Longcope C., Stanczyk F.Z., Stephenson H.E.Jr., Falk R.T., Miller R., et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J. Natl. Cancer Inst. 2003;95:1218–1226.
    1. Stender S., Nordestgaard B.G., Tybjaerg-Hansen A. Elevated body mass index as a causal risk factor for symptomatic gallstone disease: A mendelian randomization study. Hepatology. 2013;58:2133–2141. doi: 10.1002/hep.26563.
    1. Cirillo D.J., Wallace R.B., Rodabough R.J., Greenland P., LaCroix A.Z., Limacher M.C., Larson J.C. Effect of estrogen therapy on gallbladder disease. JAMA. 2005;293:330–339. doi: 10.1001/jama.293.3.330.
    1. Mamdani M.M., Tu K., van Walraven C., Austin P.C., Naylor C.D. Postmenopausal estrogen replacement therapy and increased rates of cholecystectomy and appendectomy. CMAJ. 2000;162:1421–1424.
    1. Clark J.M., Diehl A.M. Defining nonalcoholic fatty liver disease: Implications for epidemiologic studies. Gastroenterology. 2003;124:248–250. doi: 10.1053/gast.2003.50032.
    1. Portincasa P., Moschetta A., Palasciano G. Cholesterol gallstone disease. Lancet. 2006;368:230–239. doi: 10.1016/S0140-6736(06)69044-2.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する